JP2016517857A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517857A5
JP2016517857A5 JP2016509276A JP2016509276A JP2016517857A5 JP 2016517857 A5 JP2016517857 A5 JP 2016517857A5 JP 2016509276 A JP2016509276 A JP 2016509276A JP 2016509276 A JP2016509276 A JP 2016509276A JP 2016517857 A5 JP2016517857 A5 JP 2016517857A5
Authority
JP
Japan
Prior art keywords
optionally
alkyl
alkynyl
alkenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016509276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517857A (ja
JP6388915B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2014/075257 external-priority patent/WO2014173241A1/en
Publication of JP2016517857A publication Critical patent/JP2016517857A/ja
Publication of JP2016517857A5 publication Critical patent/JP2016517857A5/ja
Application granted granted Critical
Publication of JP6388915B2 publication Critical patent/JP6388915B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016509276A 2013-04-26 2014-04-14 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン Expired - Fee Related JP6388915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013074780 2013-04-26
CNPCT/CN2013/074780 2013-04-26
PCT/CN2014/075257 WO2014173241A1 (en) 2013-04-26 2014-04-14 Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

Publications (3)

Publication Number Publication Date
JP2016517857A JP2016517857A (ja) 2016-06-20
JP2016517857A5 true JP2016517857A5 (enExample) 2017-06-01
JP6388915B2 JP6388915B2 (ja) 2018-09-12

Family

ID=51791046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016509276A Expired - Fee Related JP6388915B2 (ja) 2013-04-26 2014-04-14 置換5−(3,5−ジメチルイソオキサゾール−4−イル)インドリン−2−オン

Country Status (12)

Country Link
US (2) US9393232B2 (enExample)
EP (1) EP2989096B1 (enExample)
JP (1) JP6388915B2 (enExample)
AU (1) AU2014256750B2 (enExample)
BR (1) BR112015027130A2 (enExample)
CA (1) CA2901083A1 (enExample)
EA (1) EA027139B1 (enExample)
HK (1) HK1217484A1 (enExample)
IL (1) IL240126A0 (enExample)
MX (1) MX366623B (enExample)
SG (1) SG11201506829XA (enExample)
WO (1) WO2014173241A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
US9393232B2 (en) 2013-04-26 2016-07-19 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規の置換された二環式化合物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
JP6542212B2 (ja) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメイン阻害剤としての新規キナゾリノン
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
JP6599979B2 (ja) 2014-09-15 2019-10-30 インサイト・コーポレイション Betタンパク質阻害剤として用いるための三環式複素環化合物
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CN111662226B (zh) 2015-01-28 2022-03-18 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017075377A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
CA3029851A1 (en) 2016-07-29 2018-02-01 Oncternal Therapeutics, Inc. Uses of indoline compounds such as tk216 for the treatment of cancer
GB201716392D0 (en) * 2017-10-06 2017-11-22 Glaxosmithkline Intellectual Property (No 2) Ltd Compounds
WO2020046813A1 (en) * 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN118451073A (zh) * 2021-12-29 2024-08-06 百济神州有限公司 杂环化合物
WO2025064918A1 (en) * 2023-09-20 2025-03-27 The Board Of Regents Of The University Of Texas System First-in-class phospho-brd4 inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
CN102656147A (zh) 2009-12-11 2012-09-05 霍夫曼-拉罗奇有限公司 可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
JP5968423B2 (ja) 2011-04-21 2016-08-10 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ロックリングを備えた薬用モジュール
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
JP6370368B2 (ja) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Brd4阻害剤としてのインドリノン類似体
US9393232B2 (en) 2013-04-26 2016-07-19 Beigene, Ltd. Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones

Similar Documents

Publication Publication Date Title
JP2016517857A5 (enExample)
JP7402549B2 (ja) Cxcr4阻害剤およびその使用
CN112204006B (zh) 整合应激通路的调节剂
AU2018360854B2 (en) Modulators of the integrated stress pathway
JP2013512903A5 (enExample)
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
TW201927771A (zh) 可作為蛋白質調節劑之雜環醯胺及其使用方法
US20210363136A1 (en) Modulators of the integrated stress pathway
JP2016533379A5 (enExample)
WO2019090085A1 (en) Modulators of the integrated stress pathway
BR112020008825A2 (pt) moduladores da via de estresse integrada
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
RU2014145544A (ru) Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
JP2015532295A5 (enExample)
JP2016513137A5 (enExample)
CO2018005854A2 (es) Inhibidores de la proteína quinasa, método de preparación y uso médico de los mismos
JP2015534578A5 (enExample)
JP2017537164A (ja) リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
EA201790088A1 (ru) Ингибиторы syk
US12304913B2 (en) Dihydropyrrolopyrazole derivative
JP2014518544A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
KR20200083532A (ko) 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
JP2015522018A5 (enExample)